DHR · News · 20260814N

Bioprocessing Demand and Delays

DANAHER CORP /DE/ · 2026-08-14 · Importance 25 · Surprise 32

Danaher’s bioprocessing unit missed expectations in the second quarter of 2026, weighing on connected life-sciences companies such as Bio-Rad and Sartorius. Reporting points to a potential recovery as bioprocessing shipments improve and respiratory-related headwinds fade. Danaher’s Life Sciences segment was described as achieving 5.5% core growth, supported by improved pharmaceutical spending and biotech funding. The developments suggest stabilizing bioprocessing demand is an important driver of broader life-sciences-sector recovery.

Key facts

• Danaher's Life Sciences segment showed 5.5% core growth and margin expansion. source
• Danaher is expected to have revenue growth accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. source
• DHR's valuation was described as trading at a 12% discount to its five-year average P/E. source
• Danaher reported Q2 2026 results that are detailed in the article. source